A DNA Vaccine Encoding Multiple HIV CD4 Epitopes Elicits Vigorous Polyfunctional, Long-Lived CD4(+) and CD8(+) T Cell Responses

Carregando...
Imagem de Miniatura
Citações na Scopus
40
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.6, n.2, article ID e16921, 13p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
T-cell based vaccines against HIV have the goal of limiting both transmission and disease progression by inducing broad and functionally relevant T cell responses. Moreover, polyfunctional and long-lived specific memory T cells have been associated to vaccine-induced protection. CD4(+) T cells are important for the generation and maintenance of functional CD8(+) cytotoxic T cells. We have recently developed a DNA vaccine encoding 18 conserved multiple HLA-DR-binding HIV-1 CD4 epitopes (HIVBr18), capable of eliciting broad CD4(+) T cell responses in multiple HLA class II transgenic mice. Here, we evaluated the breadth and functional profile of HIVBr18-induced immune responses in BALB/c mice. Immunized mice displayed high-magnitude, broad CD4(+)/CD8(+) T cell responses, and 8/18 vaccine-encoded peptides were recognized. In addition, HIVBr18 immunization was able to induce polyfunctional CD4(+) and CD8(+) T cells that proliferate and produce any two cytokines (IFN gamma/TNF alpha, IFN gamma/IL-2 or TNF alpha/IL-2) simultaneously in response to HIV-1 peptides. For CD4(+) T cells exclusively, we also detected cells that proliferate and produce all three tested cytokines simultaneously (IFN gamma/TNF alpha/IL-2). The vaccine also generated long-lived central and effector memory CD4(+) T cells, a desirable feature for T-cell based vaccines. By virtue of inducing broad, polyfunctional and long-lived T cell responses against conserved CD4(+) T cell epitopes, combined administration of this vaccine concept may provide sustained help for CD8(+) T cells and antibody responses-elicited by other HIV immunogens.
Palavras-chave
Referências
  1. Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759
  2. Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
  3. McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
  4. Khanolkar A, 2004, J IMMUNOL, V172, P2834
  5. Vaccari M, 2008, J VIROL, V82, P9629, DOI 10.1128/JVI.00893-08
  6. Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
  7. Potter SJ, 2007, J VIROL, V81, P13904, DOI 10.1128/JVI.01401-07
  8. Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
  9. Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935
  10. Rajasagi NK, 2009, J VIROL, V83, P5256, DOI 10.1128/JVI.01997-08
  11. Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
  12. Livingston B, 2002, J IMMUNOL, V168, P5499
  13. Yamamoto T, 2009, J VIROL, V83, P5514, DOI 10.1128/JVI.00145-09
  14. Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898
  15. Martins MA, 2010, J VIROL, V84, P4352, DOI 10.1128/JVI.02365-09
  16. Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0
  17. Okoye A, 2009, J EXP MED, V206, P1575, DOI 10.1084/jem.20090356
  18. Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
  19. Kannanganat S, 2007, J VIROL, V81, P12071, DOI 10.1128/JVI.01261-07
  20. Iwai LK, 2003, MOL MED, V9, P209
  21. Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
  22. Nitayaphan S, 2004, J INFECT DIS, V190, P702, DOI 10.1086/422258
  23. Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
  24. Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592
  25. Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07
  26. Wang M, 2009, CLIN EXP IMMUNOL, V155, P441, DOI 10.1111/j.1365-2249.2008.03856.x
  27. Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
  28. Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681
  29. Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
  30. Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
  31. Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709
  32. Sacha JB, 2009, P NATL ACAD SCI USA, V106, P9791, DOI 10.1073/pnas.0813106106
  33. Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
  34. Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
  35. Corey L, 2009, AIDS, V23, P3, DOI 10.1097/QAD.0b013e32830e6d6d
  36. Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
  37. Yang XD, 2009, REV MED VIROL, V19, P77, DOI 10.1002/rmv.602
  38. Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
  39. Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
  40. Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
  41. Pike R, 2009, J VIROL, V83, P11211, DOI 10.1128/JVI.01225-09
  42. Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
  43. Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010
  44. Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
  45. BenMohamed L, 2003, J VIROL, V77, P9463, DOI 10.1128/JVI.77.17.9463-9473.2003
  46. Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
  47. Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320
  48. Novy P, 2007, J IMMUNOL, V179, P8243
  49. ATHERTON ND, 1989, CLIN CHEM, V35, P975
  50. FERRE AL, 2010, J VIROL
  51. Giraldo-Vela JP, 2008, J VIROL, V82, P859, DOI 10.1128/JVI.01816-07
  52. Pancre V, 2007, VACCINE, V25, P5927, DOI 10.1016/j.vaccine.2007.05.038
  53. Ribeiro SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011072
  54. von Gegerfelt A, 2010, J IMMUNOL, V185, P3348, DOI 10.4049/jimmunol.1000572
  55. Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
  56. Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479